



Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference

January 6, 2025 at 8:00 AM EST

BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- [Praxis Precision Medicines](#), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be presenting a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA at the Westin St. Francis Hotel on Wednesday, January 15, 2025 at 2:15pm PST.

A live webcast of the event will be available through this [link](#). A replay of the event will also be available through the "Upcoming & Recent Events" page of the Investors + Media section of the company's website at www.praxismedicines.com, for 30 days.

About Praxis

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on [Facebook](#), [LinkedIn](#) and [Twitter/X](#).

Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors Daniel@lifesciadvisors.com 617-430-7576